


ESTTA Tracking number: **ESTTA341635**

Filing date: **04/09/2010**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding	91190284
Party	Plaintiff Graceway Pharmaceuticals, LLC
Correspondence Address	Andrea J. Mealey Edwards Angell Palmer & Dodge LLP F.D.R. Station, P.O. Box 130 New York, NY 10150 UNITED STATES trademark@eapdlaw.com, amealey@eapdlaw.com
Submission	Motion for Summary Judgment
Filer's Name	Andrea J. Mealey
Filer's e-mail	trademark@eapdlaw.com, amealey@eapdlaw.com
Signature	/Andrea J Mealey/
Date	04/09/2010
Attachments	Summary Judgment Motion and Memo.pdf ( 14 pages )(677282 bytes ) Exhibit A.pdf ( 3 pages )(71116 bytes ) Exhibit B.pdf ( 4 pages )(131758 bytes ) Exhibit C.pdf ( 4 pages )(109726 bytes ) Exhibit D.pdf ( 21 pages )(862016 bytes ) Exhibit E.pdf ( 10 pages )(338031 bytes ) Exhibit F.pdf ( 3 pages )(128534 bytes ) Exhibit G.pdf ( 3 pages )(131932 bytes ) Exhibit H.pdf ( 7 pages )(427778 bytes ) Exhibit I.pdf ( 38 pages )(1465057 bytes ) Exhibit J.pdf ( 15 pages )(751604 bytes )

I hereby certify that this correspondence is being deposited electronically with the Trademark Trial and Appeal Board on the date shown below.

  
\_\_\_\_\_

Date: April 9, 2010

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD**

IN THE MATTER OF APPLICATION SERIAL NO. 77/653,491  
MARK: ALNARA

_____	)	
GRACEWAY PHARMACEUTICALS, LLC,	)	
OPPOSER	)	
	)	
V.	)	OPPOSITION NO. 91190284
	)	
ALNARA PHARMACEUTICALS, INC.,	)	
APPLICANT	)	
_____	)	

**OPPOSER’S MOTION FOR SUMMARY JUDGMENT**


Opposer GRACEWAY PHARMACEUTICALS LLC, a Delaware limited liability company (“Opposer”), by and through its undersigned attorney, hereby moves for summary judgment pursuant to Rule 56, Fed. R. Civ. P., and Trademark Rule 2.127(e), sustaining this opposition against U.S. Trademark Application Serial No. 77/653,491 filed by Applicant ALNARA PHARMACEUTICALS, INC., a Delaware corporation (“Applicant”) for the mark “ALNARA.”

As set forth in the attached memorandum and exhibits, this Motion is made on the grounds that: (i) Opposer has priority of use; and (ii) Applicant’s mark is confusingly similar to Opposer’s “ALDARA” mark and will be used in connection with closely related goods, to be

offered in the same channels of trade to the same consumers and there thus exists a likelihood of confusion precluding registration of Applicant's mark under Section 2(d) of the Lanham Act. Accordingly, Opposer requests that it be awarded summary judgment sustaining its opposition against Application Serial No. 77/653,491 as a trial on the matter would entail unnecessary fees and waste the Board's scarce resources.

Dated: April 9, 2010

GRACEWAY  
PHARMACEUTICALS, LLC,  
BY ITS ATTORNEYS



---

Andrea J. Mealey  
amealey@capdlaw.com  
Edwards Angell Palmer & Dodge, LLP  
P.O. Box 130, F.D.R. Station  
New York, New York 10150  
Telephone: (617) 239-0388  
Facsimile: (617) 227-4420

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

IN THE MATTER OF APPLICATION SERIAL NO. 77/653,491  
MARK: ALNARA

_____	)	
GRACEWAY PHARMACEUTICALS, LLC,	)	
OPPOSER	)	
	)	
V.	)	OPPOSITION NO. 91190284
	)	
ALNARA PHARMACEUTICALS, INC.,	)	
APPLICANT	)	
_____	)	

**MEMORANDUM IN SUPPORT OF OPPOSER'S**  
**MOTION FOR SUMMARY JUDGMENT**

**I. INTRODUCTION**

Opposer GRACEWAY PHARMACEUTICALS LLC, a Delaware limited liability company ("Opposer"), respectfully submits this memorandum in support of its Motion For Summary Judgment (the "Motion"). Pursuant to Rule 56, Fed. R. Civ. P., Opposer seeks summary adjudication that, based on the facts presented herein as to which there are no genuine issues of material fact to be tried, and as a matter of law, this opposition against Application Serial No. 77/653,491 (the "Application") filed on 2009, by Applicant ALNARA PHARMACEUTICALS, INC., a Delaware corporation ("Applicant") for registration of the mark "ALNARA" for "pharmaceutical preparations for the treatment of metabolic, endocrine, gastrointestinal, digestive, rheumatologic, urological, nephrology, inflammatory, pediatric, nutritional, immunologic, cardiovascular, dermatologic, hematologic, infectious, circulatory, pulmonary, oncologic, muscular and respiratory diseases and disorders," must be sustained.

## II. PROCEDURAL AND FACTUAL BACKGROUND

Opposer acquired the trademark registration and the good will associated therewith for the mark ALDARA (the “ALDARA Mark”) from Opposer’s predecessor in interest, 3M Company (“3M”), in December 2006 pursuant to an asset purchase agreement. See Declaration of John A. A. Bellamy, attached hereto as Exhibit “A” (“Bellamy Dec.”) at ¶ 2. 3M’s predecessor in interest, Riker Laboratories, Inc., had filed an application to register the ALDARA Mark on September 14, 1994 and commenced use of the ALDARA Mark in commerce in October 1996. Id. at ¶ 4. The application for the ALDARA mark proceeded to registration on April 15, 1997. Thereafter Opposer and its predecessors have consistently advertised, sold, and provided pharmaceutical products under the mark “ALDARA” (the “ALDARA Mark”) in the United States. Id. at ¶ 5 and see Exhibit “B”, the TARR print out for the ALDARA registration. Since at least as early as October 30, 1996, Opposer, through its predecessors-in-interest, has had extensive, exclusive, and continued use of the ALDARA Mark in connection with, “pharmaceutical preparations, namely immunomodulators” (“Opposer’s Goods”). See Bellamy Dec. at ¶ 3.

On or about January 21, 2009, Applicant filed the subject Application Serial No. 77/653,491 (“ALNARA Application”) for the mark “ALNARA” (“ALNARA Mark”), in connection with “pharmaceutical preparations for the treatment of metabolic, endocrine, gastrointestinal, digestive, rheumatologic, urological, nephrology, inflammatory, pediatric, nutritional, immunologic, cardiovascular, dermatologic, hematologic, infectious, circulatory, pulmonary, oncologic, muscular and respiratory diseases and disorders,” in International Class 5 (“Applicant’s Goods”). See Exhibit “C” containing a TARR print out for the ALNARA Application attached hereto. The ALNARA Application was filed on an intent-to-use basis. Id.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.